HBM Healthcare Investments

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

Retrieved on: 
Thursday, May 20, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Life sciences, Biotechnology, Health sciences, Cancer immunotherapy, Immunotherapy, Biopharmaceutical, Numab Therapeutics, HBM Healthcare Investments, NUMAB THERAPEUTICS, HBM HEALTHCARE INVESTMENTS

b"Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.

Key Points: 
  • b"Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
  • We are thus thrilled to co-lead Numab\xe2\x80\x99s Series C financing to support the company at a pivotal stage in growth,\xe2\x80\x9d commented Nanna L\xc3\xbcneborg, Partner at Novo Ventures.\nNumab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland.
  • At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies.
  • HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210520005094/en/\n"

Dren Bio announces a $60M Series A financing

Retrieved on: 
Friday, October 16, 2020
Oncology, Professional services, Health, Genetics, Venture capital, Pharmaceutical, Biotechnology, Dren, Articles, High Performance Computing Modernization Program, Protein aggregation, Biotechnology, Protein, Branches of biology, Health, Dren Bio, SR One, Taiho Ventures, 8VC, BVF Partners L.P., HBM Healthcare Investments, Mission BioCapital, Alexandria Venture Investments

Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.

Key Points: 
  • Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.
  • Dren previously closed a $6 million Seed Financing in 2019 led by 8VC with participation by Mission BioCapital and prominent industry veterans.
  • The goal of our Series A financing is to bring two drug candidates to the clinic.
  • Dren Bio is a San Carlos, CA based biotechnology company developing powerful protein engineering technologies to deplete cells, protein aggregates and other disease-causing agents.

Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million

Retrieved on: 
Wednesday, September 16, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Immunology, Branches of biology, Health, Immune system, Biology, Antibody, Glycoproteins, Antigen, Autoimmunity, HBM Healthcare Investments, Polyneuron Pharmaceuticals

Polyneuron Pharmaceuticals AG , a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million.

Key Points: 
  • Polyneuron Pharmaceuticals AG , a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million.
  • Polyneuron will also use the proceeds to accelerate preclinical development of its Antibody-Catch product portfolio in new indications, with a focus on antibody-mediated renal and hematological diseases.
  • The interest from investors since the first closing has been phenomenal, so we decided to extend the Series A.
  • Polyneuron disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.